Home › Shanghai › Shanghai DeltaHealth Cardiovascular Hospital
◆ Private · International Hospital
Shanghai DeltaHealth Cardiovascular Hospital
上海德达心血管医院Private · International
Founded in 2016, Shanghai DeltaHealth Cardiovascular Hospital is a private hospital in Shanghai, among the top 5% of hospitals nationwide.
Get a free consultation →Specialty strengths
About
Shanghai DeltaHealth Cardiovascular Hospital is China's first wholly foreign-owned cardiovascular specialty hospital, located in Qingpu District on Shanghai's western edge. Opened in 2016 and now majority-owned by Swire Pacific, DeltaHealth was founded by a team of China's most distinguished cardiovascular physicians — including Academician Ge Junbo (cardiology) and Professor Sun Lizhong (cardiac surgery) — with a mission to create a center of excellence for heart and vascular disease. The 200-bed hospital was designed and built to JCI standards and maintains an advisory relationship with Columbia University's HeartSource program, the only such collaboration in China. DeltaHealth specializes in complex, high-acuity cardiovascular procedures: over 90% of its surgical volume consists of Grade 3-4 (the most complex) operations. In 2025, the hospital received its license as a wholly foreign-owned cardiovascular specialty hospital under China's new pilot policy — a landmark regulatory milestone that recognized its unique position in China's healthcare landscape.
History & scale
DeltaHealth was founded with a distinctive vision: rather than build a general international hospital, it would concentrate world-class cardiovascular expertise in a focused, high-volume center. The hospital opened in September 2016 with a core team of cardiovascular surgeons, cardiologists, and interventionalists who had trained at China's top cardiac centers. In 2024, Swire Pacific — the Hong Kong-listed conglomerate — increased its stake to become the controlling shareholder, bringing deep financial backing and corporate governance expertise. The hospital received its wholly foreign-owned cardiovascular specialty hospital license in March 2025, becoming the first hospital approved under China's 2024 pilot policy allowing 100% foreign ownership in select cities. DeltaHealth has steadily expanded its clinical scope, adding a radiation oncology center in 2025 and achieving national GCP (Good Clinical Practice) certification for medical device clinical trials. The hospital now records over 80,000 outpatient visits annually.
Star specialties
Cardiovascular surgery is DeltaHealth's defining strength, led by Professor Sun Lizhong — one of China's foremost aortic surgeons. The hospital performs complex procedures including aortic dissection repair, valve replacement and repair, coronary artery bypass grafting, and surgery for congenital heart disease across all age groups from infants to nonagenarians. Interventional cardiology, under Academician Ge Junbo's direction, covers coronary angioplasty and stenting, structural heart interventions (TAVR, mitral clip), and electrophysiology. The cardiac imaging program provides advanced diagnostic capability including cardiac MRI, CT angiography, and 3D echocardiography. The vascular surgery service treats peripheral arterial disease, aneurysms, and venous conditions. A recently opened radiation oncology center adds radiotherapy capability primarily for thoracic tumors. The hospital also maintains general internal medicine and ICU services to support its surgical programs.
Achievements & recognition
DeltaHealth's clinical outcomes in complex aortic surgery and structural heart interventions are benchmarked against international cardiovascular centers and published in peer-reviewed journals. In 2025, the hospital's surgeons completed a dual-chamber pacemaker implantation in a nearly 95-year-old patient and a transcatheter ventricular septal defect closure in an infant under four months — cases that demonstrate the breadth of its capability across the age spectrum. The hospital was appointed a teaching hospital of Qingdao University and has been accredited as a national GCP clinical trial site for medical devices. Its research output in 2025 included 12 published papers (5 SCI-indexed) and 4 funded research projects. The hospital hosts the annual Pangu Aortic Disease Forum, one of China's premier academic conferences in cardiovascular surgery, drawing nearly 900 participants. DeltaHealth's Columbia HeartSource advisory relationship provides ongoing clinical protocol review and quality benchmarking against US standards.
International services
DeltaHealth's international services are built for the medical traveler seeking high-complexity cardiac surgery at a cost significantly below US or European prices, with outcomes approaching international benchmarks. The hospital's international patient office coordinates the entire care journey: remote record review and surgical feasibility assessment, visa invitation letters, airport pickup, accommodation arrangements for patient and family, and post-operative follow-up planning. The hospital has direct billing agreements with over 60 international insurers, and its clinical documentation is available in English. While the hospital's primary working language is Chinese (reflecting its specialist physician team), international patient coordinators provide English-language navigation and interpretation throughout the care episode. For patients requiring treatments or devices not available in their home countries — particularly in complex aortic and structural heart disease — DeltaHealth offers access to techniques and volumes that are hard to match at many Western centers.
Why choose this hospital
DeltaHealth is the clear choice for a specific patient: someone who needs highly complex cardiovascular surgery and is willing to travel for it. The combination of China-tier pricing (typically 30-50% of US costs for comparable procedures), surgeon-level volume that rivals the world's busiest cardiac centers, and a facility purpose-built to JCI standards creates a compelling value proposition for medical travelers. The hospital's 2025 'wholly foreign-owned' license — a first for any specialist hospital in China — signals a level of regulatory confidence that is unique. For international patients who might otherwise consider India, Thailand, or Singapore for cardiac surgery, DeltaHealth offers an alternative with surgeon-scientists whose aortic and structural heart case volumes are measured in the thousands. The Swire Pacific ownership provides corporate stability and governance that international patients and referring physicians can trust.
Location & getting there
Frequently asked questions
- Where is Shanghai DeltaHealth Cardiovascular Hospital located?
- Shanghai DeltaHealth Cardiovascular Hospital is located in Shanghai, China.
- Is Shanghai DeltaHealth Cardiovascular Hospital a reputable hospital?
- Shanghai DeltaHealth Cardiovascular Hospital is a Class III-A hospital — the highest tier in China's grading system, held by only about 5% of hospitals nationwide.
- Can international patients visit Shanghai DeltaHealth Cardiovascular Hospital?
- Yes. International patients are advised to contact the hospital ahead of the visit to confirm appointment procedures and language support (4008-210-277).
